Core Viewpoint - UBS has added Kangfang Biotech (09926) to its list of major recommended stocks in the Asia-Pacific region, citing that the overseas potential of its main asset, Edafo, is not fully reflected in the stock price [1] Group 1: Company Analysis - UBS believes that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress will serve as positive catalysts for the stock price [1] - The target price for Kangfang Biotech has been raised from HKD 197.5 to HKD 224.3, with a "Buy" rating assigned [1] - The valuation of Kangfang Biotech is approximately at the median of the biotech stocks covered by UBS, indicating potential for further outperformance [1] Group 2: Sales Forecasts - UBS has increased its peak sales estimate for Edafo from USD 14.6 billion to USD 16.3 billion [1] - The peak sales estimate for another key asset, Kantani, has been raised from USD 2.2 billion to USD 3.4 billion [1]

Group 1 - Kangfang Biotech (09926) shares rose over 4%, reaching a new high of 173.8 HKD, with a trading volume of 1.212 billion HKD [1] - The 2025 World Lung Cancer Conference (WCLC) will take place from September 6 to 9 in Barcelona, Spain, where Kangfang's partner Summit Therapeutics will present the results of the HARMONi study, a pivotal Phase III clinical trial for the PD-1/VEGF bispecific antibody drug, Ivoris [1] Group 2 - UBS has added Kangfang Biotech to its list of major recommended stocks in the Asia-Pacific region, citing the overseas potential of its main asset, Ivoris, which is not fully reflected in the stock price [2] - The firm believes that reports of potential collaborations with multinational companies and the upcoming HARMONi study results will act as positive catalysts for the stock price [2] - UBS raised its peak sales forecast for Ivoris from 14.6 billion USD to 16.3 billion USD and for another key asset, Kantan, from 2.2 billion USD to 3.4 billion USD, increasing the target price from 197.5 HKD to 224.3 HKD with a "Buy" rating [2]

Group 1 - 康方生物's stock price increased over 4%, reaching a new high of 173.8 HKD, with a trading volume of 1.212 billion HKD [1] - The 2025 World Lung Cancer Conference (WCLC) will take place in Barcelona, Spain, where 康方生物's partner Summit Therapeutics will present the results of the HARMONi study, a pivotal Phase III clinical trial for the PD-1/VEGF bispecific antibody drug [1] Group 2 - UBS has added 康方生物 to its list of major recommended stocks in the Asia-Pacific region, citing the overseas potential of its main asset, Edafo, which is not fully reflected in the stock price [2] - The firm believes that news regarding potential collaborations with multinational companies and the upcoming HARMONi study results will act as positive catalysts for the stock price [2] - UBS raised its peak sales forecast for Edafo from 14.6 billion USD to 16.3 billion USD and for another key asset, Okan, from 2.2 billion USD to 3.4 billion USD, while increasing the target price from 197.5 HKD to 224.3 HKD with a "Buy" rating [2]

Group 1 - The market sentiment is bullish, with both Hong Kong and A-shares rising, and the Shanghai Composite Index reaching a 10-year high [1] - The Hang Seng Innovative Drug ETF (159316) increased by over 3.3% today, marking a 76.5% rise since its launch at the end of March this year, achieving a new net asset value high [1] - The Hang Seng Innovative Drug ETF is currently the only ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on high-purity and high-elasticity stocks, including leading innovative drug companies [1] Group 2 - Recent adjustments to the Hang Seng Hong Kong Stock Connect Innovative Drug Index have removed CXO companies, resulting in a 100% concentration of innovative drug components [1] - The Hang Seng Innovative Drug ETF (159316) has attracted significant capital, with a net inflow of 663 million yuan since the second half of this year, bringing its latest scale to 1.258 billion yuan, a 357% increase since its launch [1] - Tianfeng Securities indicates that with the upcoming concentrated release period for innovative drugs and continued government policy support, the development trend and industrial upgrade of the innovative drug sector are becoming clearer [1]

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical sector, indicating that it is expected to outperform the market [4][6]. Core Insights - The innovative drug sector is poised for a new round of catalysts, with significant research results expected from upcoming conferences such as WCLC and ESMO [2][4]. - The SW pharmaceutical index increased by 3.08% during the week, outperforming the CSI 300 index, reflecting a strong market recovery [4]. - Global demand for weight loss drugs remains high, as evidenced by Eli Lilly's 170% price increase for Mounjaro in the UK and the FDA approval of semaglutide for treating MASH [4]. Summary by Sections Industry Performance - The pharmaceutical sector has shown resilience, with the SW pharmaceutical index outperforming the CSI 300 index during a market rebound [4]. - The sector's performance is supported by strong gains in related indices, such as the Hang Seng Biotechnology Index and the Hang Seng Healthcare Index [4]. Upcoming Catalysts - Key international academic conferences are set to unveil important research results, which could enhance the visibility and credibility of Chinese innovative drugs on a global scale [4]. - Notable presentations are expected from companies like Kangfang Biopharma and Basilea Pharmaceutica at these conferences [4]. Market Trends - The global weight loss drug market is experiencing robust growth, with significant developments from major pharmaceutical companies [4]. - The report highlights the potential for Chinese innovative drugs to enter international markets, particularly in the ADC and PD-1 dual antibody segments [4]. Investment Strategy - The report suggests focusing on three main investment themes: the international expansion of innovative drugs, high-growth CXO companies, and the revaluation of Big Pharma pipelines [4]. - Specific companies to watch include WuXi AppTec, Innovent Biologics, and Kangfang Biopharma, among others [4].

Core Viewpoint - UBS has added Kangfang Biopharma to its list of major recommended stocks in the Asia-Pacific region, believing that the overseas potential of its key asset, Edafo, is not fully reflected in its stock price [1] Group 1: Company Potential - UBS highlights that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress serve as positive catalysts for the stock price [1] - The company is also advancing the global registration and research of another key asset, Okanani [1] Group 2: Financial Estimates - UBS has raised its peak sales forecast for Edafo from $14.6 billion to $16.3 billion and for Okanani from $2.2 billion to $3.4 billion [1] - The target price for Kangfang Biopharma has been increased from HKD 197.5 to HKD 224.3, maintaining a "Buy" rating [1]

Group 1 - The overall performance of the Hong Kong stock market is positive, with the innovative drug sector continuing its strong performance from the previous week, supported by solid fundamentals and high trading sentiment [1] - Southbound funds net bought HK stocks worth HKD 35.876 billion on August 15, setting a new record for single-day net inflow since the launch of the mutual market access mechanism in November 2014, with the innovative drug sector receiving a net inflow of HKD 1.042 billion [1] - The Hang Seng Innovative Drug ETF (520500) attracted a net inflow of HKD 117 million from August 11 to August 15, marking the highest weekly net inflow in nearly three months, and its total size reached HKD 1.351 billion, with a year-to-date increase of over 1000% [1] Group 2 - The Hang Seng Innovative Drug ETF (520500) closely tracks the Hang Seng Innovative Drug Index, which selects listed companies in the Hong Kong market related to innovative drug research, development, and production, emphasizing the exclusion of companies primarily engaged in the CXO industry [2] - The index's top five constituent stocks as of August 15 include BeiGene, CanSino Biologics, Innovent Biologics, China National Pharmaceutical Group, and Kelun-Biotech [2] - The national medical security work mid-year meeting held on August 15 emphasized empowering the pharmaceutical industry innovation and implementing measures to support high-quality development of innovative drugs, indicating continued policy support for the innovative drug sector [2] Group 3 - The manager of the Hang Seng Innovative Drug ETF (520500), Huatai-PB Fund, is one of the first ETF managers in China, known for creating leading ETFs such as the CSI 300 ETF and A500 ETF, maintaining an 18-year record of zero errors in ETF operations [3] - As of August 15, the size of the CSI 300 ETF is CNY 393.42 billion, and the A500 ETF is CNY 20.113 billion [3] - The Hang Seng Innovative Drug ETF (520500) was established on December 16, 2024, and supports T+0 trading, enhancing its liquidity advantage [3]

Investment Rating - The report maintains an investment rating of "B" for the biopharmaceutical industry, indicating that it is expected to outperform the market [1][3]. Core Insights - The report highlights that tumor immunotherapy (IO) is a cornerstone treatment for non-small cell lung cancer (NSCLC), with next-generation IO therapies based on PD-1/L1 monoclonal antibodies showing promise when combined with VEGF, IL-2, ADC, and CTLA-4 to overcome immune resistance and improve survival rates [3][4]. - PD-1/VEGF dual antibodies have demonstrated significant clinical benefits in first-line progression-free survival (PFS) and overall survival (OS) settings, while PD-L1 ADCs offer new options for immune-resistant cases [3][4]. - The report notes that the combination of PD-1/VEGF dual antibodies with chemotherapy has outperformed PD-1 monoclonal antibodies combined with chemotherapy in clinical trials [3][4]. Summary by Sections Tumor Immunotherapy Developments - The report discusses the efficacy of various ADC drugs in NSCLC, including TROP2, EGFR×HER3, and PD-L1 ADCs, which have shown outstanding results [3]. - PD-1/VEGF dual antibodies have reached PFS endpoints in clinical trials for squamous NSCLC, with an overall response rate (ORR) of 71.4% and a median duration of response (mDOR) of 12.7 months [4]. Clinical Trial Results - In first-line PD-L1 positive NSCLC, the ORR for the 707 single-agent treatment was 70.8%, while the combination with chemotherapy yielded an ORR of 58.3% for non-squamous and 81.3% for squamous NSCLC [4]. - The report also highlights the significant OS benefits observed with the PD-1/IL-2α-bias dual antibody fusion protein IBI363 in previously treated squamous NSCLC, achieving a median OS of 15.3 months [5]. Emerging Therapies - The PD-L1 ADC HLX43 has shown an ORR of 31.9% in CPI-treated NSCLC, with a notable 47.4% ORR in the EGFR wild-type non-squamous NSCLC subgroup [6]. - The report emphasizes the potential of the PD-1/VEGF/CTLA-4 triple antibody CS2009, which has demonstrated anti-tumor activity in early clinical trials [6].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The initial review of the commercial insurance innovative drug directory has been approved, indicating a continuous expansion of payment space [2][21]. - The report highlights the importance of focusing on companies with strong R&D capabilities and existing commercialized innovative drug products, such as BeiGene, Hengrui Medicine, Innovent Biologics, and Kangfang Bio [2][25]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 3.08%, outperforming the CSI 300 index by 0.77 percentage points, but underperforming the ChiNext index by 2.76 percentage points, ranking 10th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index increased by 7.12%, outperforming the Hang Seng Index by 5.51 percentage points [1][15]. Company R&D Progress - Recent IND applications include Hengrui Medicine's HRS-4729 injection and HRS-7172 tablets, as well as clinical applications for Kangnuo's CM536 injection and Sanofi's SSS50 injection [28]. Key Company Profit Forecasts and Valuation - Hengrui Medicine: EPS forecast for 2024 is 0.99 CNY, with a PE ratio of 64, rated as "Accumulate" [4]. - Yuyue Medical: EPS forecast for 2024 is 1.80 CNY, with a PE ratio of 20, rated as "Buy" [4]. - Mindray Medical: EPS forecast for 2024 is 9.62 CNY, with a PE ratio of 24, rated as "Buy" [4]. - United Imaging Healthcare: EPS forecast for 2024 is 1.53 CNY, with a PE ratio of 84, rated as "Buy" [4]. Payment Perspective Strategy - The report emphasizes the need to select investment opportunities structurally, focusing on the core contradiction between payment willingness and ability [3][25]. - It identifies three key payment channels: hospital payments, out-of-pocket payments, and overseas payments, recommending companies like Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [3][25]. Innovative Drug Directory Insights - A total of 121 drugs passed the initial review for the commercial insurance innovative drug directory, with 79 drugs appearing in both the basic medical insurance and commercial insurance directories, providing a "double insurance" effect [2][22]. - The report notes that targeted therapies, particularly PD-(L)1 monoclonal antibodies, dominate the applications for the commercial insurance directory [2][23].

Core Viewpoint - The Hong Kong technology stocks are experiencing a significant revaluation, driven by strong earnings reports, particularly from Tencent, which has led to increased target prices from over 20 Wall Street analysts [1][2]. Group 1: Market Performance and Analyst Predictions - Following Tencent's earnings report, at least 16 brokerage firms predict that its stock price may surpass historical highs, with Goldman Sachs raising its target price from 658 HKD to 701 HKD and adjusting revenue and earnings forecasts for 2025 to 2027 upwards by 1% to 6% [1]. - The "Hong Kong Stock Connect Technology ETF Fund" (code: 159101) has gained investor attention since its issuance began on August 18, aiming to closely track the "National Index Hong Kong Stock Connect Technology Index" [1][2]. Group 2: Financial Indicators and Market Sentiment - Recent financial indicators suggest a recovery in the revenue growth rate of the Hong Kong technology sector, stabilizing around 15%, with profit growth turning positive and frequently exceeding expectations [2][8]. - The valuation metrics for the Hong Kong technology sector indicate a price-to-earnings ratio of 24.41 and a price-to-sales ratio of 2.92, which are at 27.27% and 45.02% percentile points since the index's inception, respectively [2]. Group 3: Investment Trends and Foreign Capital Inflows - Foreign capital is increasingly attracted to Hong Kong technology stocks, with a notable net inflow of approximately 27 billion USD (about 194 billion RMB) into the Chinese stock market in July, indicating a strong trend of returning investment [8][10]. - The southbound capital flow has also provided substantial support to the Hong Kong technology sector, with a record net purchase of approximately 358.76 billion HKD on August 15, surpassing the total net inflow for the previous year [8]. Group 4: Future Growth Drivers - The upcoming release of new games and advancements in AI technology are expected to drive Tencent's growth, with the anticipated mobile game "Valorant Mobile" set to launch soon [1][2]. - The potential for further liquidity improvements from the Federal Reserve's anticipated interest rate cuts is expected to benefit the Hong Kong technology sector, enhancing its market resilience [10][11]. Group 5: ETF Fund Performance - The "Hong Kong Stock Connect Technology ETF Fund" aims to track the "National Index Hong Kong Stock Connect Technology Index," which has shown a cumulative return of 159.9% since 2017, outperforming other indices [11][12]. - The top holdings in the index include major companies such as Tencent, Alibaba, and BYD, with a significant allocation to innovative pharmaceutical sectors, which has contributed to the index's strong performance [14][15].